Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart.
Although hyperglycemia is one factor that determines the outcome of myocardial ischemic insult, it is still not clear whether it is causally related to decreased ischemic tolerance in diabetic patients. In contrast to clinical and epidemiological studies demonstrating a higher risk of cardiovascular disorders in diabetic patients, experimental data are not unequivocal and suggest that, aside from higher myocardial vulnerability, diabetes mellitus may be associated with the triggering of adaptive processes leading to paradoxically lower susceptibility to ischemia. It has been proposed that this phenomenon shares some molecular pathways with short-term preconditioning and other forms of endogenous protection against ischemia/reperfusion injury in the nondiseased heart. The present article reviews some controversial findings of enhanced resistance to ischemia in the diabetic heart that stem from experimental studies in different models of myocardial ischemia/reperfusion injury. Specifically, it addresses the issue of potential mechanisms of increased resistance to ischemia in an experimental model of streptozotocin-induced diabetes, particularly with respect to the role of reactive oxygen species, hyperglycemia as one of the stress factors, and cell-signalling mechanisms mediated by 'prosurvival' cascades of protein kinases in relation to the mechanisms of classical ischemic preconditioning. Finally, mechanisms involved in the suppression of protection in the diabetic myocardium including the effect of concomitant pathology, such as hypercholesterolemia, are discussed.
Institute for Heart Research, Slovak Academy of Sciences and Centre of Excellence for Cardiovascular Research SAS;
T
T
Ravingerová
A
A
Adameová
J
J
Matejíková
T
T
Kelly
M
M
Nemčeková
J
J
Kucharská
O
O
Pecháňová
A
A
Lazou
Cardiovasc Res. 1993 Apr;27(4):644-51
8324799
Mol Cell Biochem. 2000 Jul;210(1-2):143-51
10976767
Gen Physiol Biophys. 2005 Dec;24(4):411-26
16474186
Physiol Res. 2009;58(3):443-447
19627174
Mol Cell Biochem. 1992 Feb 12;109(2):173-9
1320733
Can J Physiol Pharmacol. 2009 Dec;87(12):1028-36
20029539
J Cardiovasc Electrophysiol. 1995 Nov;6(11):1039-62
8589873
J Pharmacol Exp Ther. 2006 Jan;316(1):154-61
16166272
Clin Sci (Lond). 1996 Oct;91(4):441-8
8983869
J Mol Cell Cardiol. 1998 Sep;30(9):1869-75
9769241
Cardiovasc Res. 1990 Nov;24(11):873-8
2272064
Physiol Res. 2008;57 Suppl 2:S55-S60
18373392
Life Sci. 1999;65(18-19):1999-2001
10576454
J Biochem Mol Toxicol. 2003;17(1):24-38
12616644
J Physiol. 1995 Nov 1;488 ( Pt 3):673-88
8576857
Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H1948-54
10843893
Diabetes Res Clin Pract. 1996 Jul;31 Suppl:S113-22
8864649
Exp Mol Pathol. 2004 Feb;76(1):57-65
14738870
Annu Rev Physiol. 2007;69:51-67
17007587
Bratisl Lek Listy. 2001;102(11):515-9
11901708
Cardiovasc Res. 1997 Apr;34(1):113-20
9217880
Ann N Y Acad Sci. 2002 Jun;967:463-8
12079875
Rev Port Cardiol. 1996 Oct;15(10):703-8
9115763
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H224-30
16936002
Basic Res Cardiol. 2001 Apr;96(2):160-8
11327334
Diabetes. 1994 Jun;43(6):831-5
8194671
Mol Cell Biochem. 2003 Jul;249(1-2):167-74
12956412
Mol Cell Biochem. 1996 May 10;158(1):43-51
8791283
Diabetologia. 2006 Mar;49(3):598-606
16425033
J Mol Cell Cardiol. 1995 Sep;27(9):1883-94
8523449
Eur J Pharmacol. 2007 Dec 8;576(1-3):114-21
17764671
Circ J. 2003 Nov;67(11):955-61
14578604
J Thorac Cardiovasc Surg. 1996 Sep;112(3):778-86
8800168
Circ Res. 1988 May;62(5):931-40
3359577
Circ Res. 2004 Sep 17;95(6):568-78
15375023
Circ Res. 1997 Dec;81(6):1027-33
9400384
Mol Cell Biochem. 2007 Jan;295(1-2):129-36
16900395
Am J Physiol. 1990 Jan;258(1 Pt 2):H255-61
2154133
Nature. 1983 Sep 8-14;305(5930):147-8
6310409
Diabetes Res Clin Pract. 1996 Jul;31 Suppl:S105-12
8864648
Neurosci Behav Physiol. 2007 Jun;37(5):489-93
17505800
Cardiovasc Res. 2006 May 1;70(2):240-53
16545352
Circulation. 1993 Mar;87(3):881-92
8443909
Diabetes. 2005 Aug;54(8):2360-4
16046302
Acta Physiol (Oxf). 2007 Nov;191(3):171-88
17935522
Cardiovasc Res. 1997 Apr;34(1):104-12
9217879
Eur J Pharmacol. 2005 May 16;515(1-3):142-9
15894305
Life Sci. 1985 Aug 12;37(6):547-51
4021729
Jpn J Physiol. 1999 Oct;49(5):409-15
10603424
Cardiovasc Res. 2004 Feb 15;61(3):512-21
14962481
Circulation. 1979 Jan;59(1):8-13
758126
Circulation. 1993 Sep;88(3):1273-8
8353889
J Mol Cell Cardiol. 1992 Apr;24(4):411-21
1619670
Clin Exp Pharmacol Physiol. 2006 Oct;33(10):910-6
17002667
Cardiovasc Res. 2006 Feb 1;69(2):450-8
16330008
Physiol Res. 2009;58(1):9-19
18198991
J Mol Cell Cardiol. 1995 Jan;27(1):169-79
7760340
Adv Cardiol. 2008;45:154-170
18230961
Cardiovasc Res. 1996 Apr;31(4):526-36
8689644
Mol Cell Biochem. 2003 Jul;249(1-2):59-65
12956399
Cardiovasc Res. 1998 Nov;40(2):239-47
9893715
Eur J Heart Fail. 2010 Jul;12(7):659-67
20406798
Cardiovasc Res. 1993 Nov;27(11):1908-12
8287395
J Am Coll Cardiol. 1998 Apr;31(5):950-6
9561992
Mol Cell Biochem. 1997 Nov;176(1-2):191-8
9406161
Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):415-27
16955284
Cell Mol Biol (Noisy-le-grand). 1992 Nov;38(7):739-49
1472901
Heart Fail Rev. 2007 Dec;12(3-4):181-8
17516169
Circ Res. 1991 Apr;68(4):1127-37
2009612
Circulation. 1994 Aug;90(2):700-5
8044938
Biochim Biophys Acta. 2007 Aug;1767(8):1007-31
17631856
Can J Physiol Pharmacol. 2008 Apr;86(4):166-72
18418425
Circ Res. 1992 Feb;70(2):223-33
1310443
Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1343-50
15894568
Adv Exp Med Biol. 2001;498:213-20
11900371